Alvotech (ALVO)

$3.38 0.00 (N/A)
Market Cap 1.02B
Revenue (ttm) 586.32M
Net Income (ttm) 27.92M
EPS (ttm) N/A
PE Ratio 35.00
Forward PE 312.70
Profit Margin 4.76%
Debt to Equity Ratio -4.57
Volume 460,100
Avg Vol 586,940
Day's Range N/A - N/A
Shares Out 301.81M
Stochastic %K 13%
Beta 0.25
Analysts Sell
Price Target $6.60

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Address:
9, Rue de Bitbourg, Luxembourg, Luxembourg
Kosmokrat
Kosmokrat Apr. 24 at 5:33 PM
$ALVO will publish Q1 results on May 6, hold an earnings call on May 7. I assume they will do their best to refile the BLA to the FDA for AVT05 before that. If they don't file it by then, at least we'll get an update in the earnings call.
0 · Reply
Kosmokrat
Kosmokrat Apr. 23 at 12:29 PM
$ALVO You can see this with so many biotechs: "The market" gets disappointed with the ramp up of the commercialization phase. After the "Multi Billion Dollar Addressable Market Phase" comes the "Commercialization" phase, and the shift in valuation is very painful. From opportunity size to "Enterprise Value-to-Sales". Usually during this shift there is a multi-year low-point of share price. However, this is where I love to invest. You can make a lot of money here. But the bottom is impossible to predict. Usually it goes much lower than what I predict, sometimes it does not go low enough to trigger my entry point. For $ALVO I loaded my boat big times. Willing to wait a few years to see double digits again.
0 · Reply
Kosmokrat
Kosmokrat Apr. 22 at 7:13 PM
$ALVO 2026 will be the first year $ALVO will be cash flow positive and hopefully even profitable, even without any US launches. I guess the market wants some proof, before the stock will go higher. Execution is key now for $ALVO. But with more than 30 biosimilars in the pipeline and their track record of delivering phenomenal growth through worldwide partnerships, I think they are grossly undervalued right now. I am full loaded right now, willing to hold until we reach double digits again in two or three years!
1 · Reply
Toffik72
Toffik72 Apr. 16 at 6:51 AM
$ALVO interview with Wessman in swedish press from 30.03. 2026. https://www.placera.se/telegram/alvotech-alvotech-vi-kan-initiera-en-ny-biosimilar-varannan-manad-vd-20260331
0 · Reply
Toffik72
Toffik72 Apr. 15 at 4:37 AM
$ALVO Big drop of Stelara sales in Q1 . The question is who is best positioned to get these market shares? Do you think Alvotech (Selarsdi) with 15–25% is realistic?
1 · Reply
diggs24
diggs24 Apr. 14 at 8:35 PM
$ALVO I've got more ammo. Drop it further....
0 · Reply
diggs24
diggs24 Apr. 7 at 5:14 PM
$ALVO Added 479@$3.44
1 · Reply
Rphin
Rphin Apr. 6 at 10:26 PM
$ALVO up almost 22% in the last 5 sessions! 👍
2 · Reply
JohnTill
JohnTill Apr. 4 at 6:49 PM
$ALVO 4.10-4.25 coming within the next 5-7 trading session? Way too obvious? So many things lining up on the chart saying this is the next move (falling wedge, 50MA, etc, etc.). The fundamentals scream double digits within the next 18 months with FDA, US partner and new drug news coming soon so I should not even care but happy with some small baby steps. Now I am pissed I did not more than double up below 3.25 when given the chance but at least now well into the money on the trade. See where the week takes us.
0 · Reply
JohnTill
JohnTill Apr. 1 at 2:39 PM
$ALVO This would be a VERY good time for the company to put out FDA news or annouce a new US partner agreement. Finally some momentum in the right direction at that 50MA at 4.27 is just itching to get tested on news. After that - the GAP! At least I am well into the profit side again with more then tripling my position below 3.25 that in late March. I was definitely not loving buying into the that hole and on to brighter days.
0 · Reply
Latest News on ALVO
Alvotech to Report Financial Results for the First Quarter of 2026

Apr 24, 2026, 8:30 AM EDT - 1 day ago

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech files Annual Report with the SEC

Mar 30, 2026, 7:58 PM EDT - 25 days ago

Alvotech files Annual Report with the SEC

Alvotech Publishes 2025 Annual Report

Mar 30, 2026, 7:55 PM EDT - 25 days ago

Alvotech Publishes 2025 Annual Report

Alvotech Q4 2025 and Full Year 2025 Financial Results

Mar 18, 2026, 6:15 PM EDT - 5 weeks ago

Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 3:00 AM EST - 7 weeks ago

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech Announces Increase in Number of Own Shares

Feb 11, 2026, 11:00 AM EST - 2 months ago

Alvotech Announces Increase in Number of Own Shares

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Feb 5, 2026, 3:00 AM EST - 2 months ago

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Feb 2, 2026, 3:00 AM EST - 2 months ago

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm

Jan 13, 2026, 3:22 PM EST - 3 months ago

Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm

BYND

Correction: Transactions of Managers and Closely Associated Persons

Jan 7, 2026, 5:00 PM EST - 3 months ago

Correction: Transactions of Managers and Closely Associated Persons

Transactions of Managers and Closely Associated Persons

Jan 6, 2026, 3:00 PM EST - 3 months ago

Transactions of Managers and Closely Associated Persons

Alvotech Secures Term Loan Facility of USD 100 Million

Dec 31, 2025, 4:30 PM EST - 4 months ago

Alvotech Secures Term Loan Facility of USD 100 Million

Changes in company's own shares

Dec 29, 2025, 2:40 PM EST - 4 months ago

Changes in company's own shares

Alvotech's Financial Calendar for 2026

Dec 22, 2025, 3:26 PM EST - 4 months ago

Alvotech's Financial Calendar for 2026

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Dec 22, 2025, 2:00 AM EST - 4 months ago

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Dec 17, 2025, 4:08 PM EST - 4 months ago

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Dec 17, 2025, 2:30 AM EST - 4 months ago

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Nov 24, 2025, 5:30 AM EST - 5 months ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Nov 20, 2025, 4:00 AM EST - 5 months ago

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Nov 12, 2025, 4:40 PM EST - 5 months ago

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 10, 2025, 5:28 PM EST - 5 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 6:28 PM EST - 6 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Nov 6, 2025, 9:07 AM EST - 6 months ago

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Nov 4, 2025, 4:01 PM EST - 6 months ago

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Alvotech Shares Plunge 33% After FDA Flags Issues

Nov 3, 2025, 1:17 PM EST - 6 months ago

Alvotech Shares Plunge 33% After FDA Flags Issues

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Nov 2, 2025, 5:12 PM EST - 6 months ago

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 22, 2025, 5:00 AM EDT - 6 months ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Oct 6, 2025, 4:40 AM EDT - 7 months ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Sep 22, 2025, 6:15 AM EDT - 7 months ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Sep 22, 2025, 4:30 AM EDT - 7 months ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Sep 19, 2025, 7:45 AM EDT - 7 months ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Sep 4, 2025, 9:15 AM EDT - 8 months ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Aug 21, 2025, 4:30 AM EDT - 8 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Aug 20, 2025, 6:05 AM EDT - 8 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 9 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 9 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Aug 6, 2025, 8:00 AM EDT - 9 months ago

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Jul 10, 2025, 4:40 AM EDT - 10 months ago

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Jul 9, 2025, 4:30 AM EDT - 10 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Jul 9, 2025, 4:30 AM EDT - 10 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Jul 3, 2025, 7:02 PM EDT - 10 months ago

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Granting of Stock Options and Vesting of Restricted Share Units

Jul 1, 2025, 7:54 PM EDT - 10 months ago

Granting of Stock Options and Vesting of Restricted Share Units

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Jul 1, 2025, 4:00 AM EDT - 10 months ago

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Jun 26, 2025, 4:15 AM EDT - 10 months ago

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Kosmokrat
Kosmokrat Apr. 24 at 5:33 PM
$ALVO will publish Q1 results on May 6, hold an earnings call on May 7. I assume they will do their best to refile the BLA to the FDA for AVT05 before that. If they don't file it by then, at least we'll get an update in the earnings call.
0 · Reply
Kosmokrat
Kosmokrat Apr. 23 at 12:29 PM
$ALVO You can see this with so many biotechs: "The market" gets disappointed with the ramp up of the commercialization phase. After the "Multi Billion Dollar Addressable Market Phase" comes the "Commercialization" phase, and the shift in valuation is very painful. From opportunity size to "Enterprise Value-to-Sales". Usually during this shift there is a multi-year low-point of share price. However, this is where I love to invest. You can make a lot of money here. But the bottom is impossible to predict. Usually it goes much lower than what I predict, sometimes it does not go low enough to trigger my entry point. For $ALVO I loaded my boat big times. Willing to wait a few years to see double digits again.
0 · Reply
Kosmokrat
Kosmokrat Apr. 22 at 7:13 PM
$ALVO 2026 will be the first year $ALVO will be cash flow positive and hopefully even profitable, even without any US launches. I guess the market wants some proof, before the stock will go higher. Execution is key now for $ALVO. But with more than 30 biosimilars in the pipeline and their track record of delivering phenomenal growth through worldwide partnerships, I think they are grossly undervalued right now. I am full loaded right now, willing to hold until we reach double digits again in two or three years!
1 · Reply
Toffik72
Toffik72 Apr. 16 at 6:51 AM
$ALVO interview with Wessman in swedish press from 30.03. 2026. https://www.placera.se/telegram/alvotech-alvotech-vi-kan-initiera-en-ny-biosimilar-varannan-manad-vd-20260331
0 · Reply
Toffik72
Toffik72 Apr. 15 at 4:37 AM
$ALVO Big drop of Stelara sales in Q1 . The question is who is best positioned to get these market shares? Do you think Alvotech (Selarsdi) with 15–25% is realistic?
1 · Reply
diggs24
diggs24 Apr. 14 at 8:35 PM
$ALVO I've got more ammo. Drop it further....
0 · Reply
diggs24
diggs24 Apr. 7 at 5:14 PM
$ALVO Added 479@$3.44
1 · Reply
Rphin
Rphin Apr. 6 at 10:26 PM
$ALVO up almost 22% in the last 5 sessions! 👍
2 · Reply
JohnTill
JohnTill Apr. 4 at 6:49 PM
$ALVO 4.10-4.25 coming within the next 5-7 trading session? Way too obvious? So many things lining up on the chart saying this is the next move (falling wedge, 50MA, etc, etc.). The fundamentals scream double digits within the next 18 months with FDA, US partner and new drug news coming soon so I should not even care but happy with some small baby steps. Now I am pissed I did not more than double up below 3.25 when given the chance but at least now well into the money on the trade. See where the week takes us.
0 · Reply
JohnTill
JohnTill Apr. 1 at 2:39 PM
$ALVO This would be a VERY good time for the company to put out FDA news or annouce a new US partner agreement. Finally some momentum in the right direction at that 50MA at 4.27 is just itching to get tested on news. After that - the GAP! At least I am well into the profit side again with more then tripling my position below 3.25 that in late March. I was definitely not loving buying into the that hole and on to brighter days.
0 · Reply
JohnTill
JohnTill Mar. 31 at 2:38 AM
$ALVO ALVO 20-F released and explains the strength today. I checked the SEC account mid-day and saw nothing but up there now. Well written all public items and could not find anything of major note. The major item is the next 9 months hinges on FDA approval. Approval by October and they will hit the high end of projections and more than enough cash flow for full speed expansion and debt knock-down. I see no reason why they will not get FDA approval and the only question is Sept. or Dec. and two years from now makes little difference. I do like that along with 30+ biosimilars in the pipeline they also talk about acquiring or in-license additional products and expansion into more expensive clinical programs. There are so many bullets in this gun and each one is a billion+ dollar target.
0 · Reply
JohnTill
JohnTill Mar. 30 at 7:49 PM
$ALVO Weird strength in a weak market on no news. Did someone let the cat out of the bag that the FDA filing is coming very soon or the new US partner agreement? Maybe UBS analyst Ashwani Verma buy rating from last week is finally making the rounds. Only a 6.00 price target but that is because everyone is holding out for FDA approval, new US partner and US drug launch. Once those hit we fill the gap and double digits and a rollercoaster until then.
0 · Reply
JohnTill
JohnTill Mar. 26 at 3:57 PM
$ALVO We could use some good news. I just noticed in the conference call notes “So that is why we're in the final stretches of being ready to submit. We're working really hard to do it by the end of the first quarter.”….. FDA news in the next few days? All changes done and running since late 2025. Filing starts the 6 month timer and inventory ready to flood the US potentially as soon as Oct. Also, could get the US partner news anytime and several pipeline updates. Upped my position by 40% this past few days between 3.22 and 3.05. Sitting with mid-3 avg. now and second largest position. Let the sweating starts. Delays get us into the twos and will add more since there is no way this is not healthy double digits by 2028 or sooner.
0 · Reply
Spytime
Spytime Mar. 26 at 1:20 PM
$ALVO waiting to open buy position soon. Waiting for panic retail to sell.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 24 at 11:42 PM
$ALVO RSI: 31.19, MACD: -0.3075 Vol: 0.28, MA20: 3.77, MA50: 4.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Mar. 24 at 2:44 PM
Barclays maintains Alvotech $ALVO at Underweight and lowers the price target from $5 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Explorer2234
Explorer2234 Mar. 24 at 2:35 PM
$ALVO lol wtf is going on with the price? Massive upside potential?
0 · Reply
diggs24
diggs24 Mar. 24 at 2:22 PM
$ALVO added 580@$3.07
0 · Reply
Toffik72
Toffik72 Mar. 24 at 9:13 AM
$ALVO UBS analyst Ashwani Verma reiterated a Buy rating on Alvotech today and set a price target of $6.00. https://www.tipranks.com/news/ratings/alvotech-regulatory-setbacks-priced-in-biosimilar-strength-supports-buy-rating-despite-lowered-target-ratings-news?utm_source=marketchameleon.com&utm_medium=referral
0 · Reply
diggs24
diggs24 Mar. 23 at 5:15 PM
$ALVO Added 550@$3.35
0 · Reply
Kosmokrat
Kosmokrat Mar. 23 at 3:40 PM
$ALVO just completed another round of financing in December, which should be sufficient until they are cash-flow positive. Which they should be this year. Remember, their sales are ramping up, while the new FDA guidance to no longer requires phase 3 studies for biosimilars, which reduces cost significantly for them.
0 · Reply